Loading clinical trials...
Loading clinical trials...
A SINGLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF ILV-095 ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH PSORIASIS.
Conditions
Interventions
ILV-095 300 mg in a 4 to 1 ratio
ILV-095 300 mg in a 4 to 1 ratio
Locations
9
United States
Cetero Research
Miami Gardens, Florida, United States
Miami Research Associates, Inc.
South Miami, Florida, United States
MRA Clinical Research
South Miami, Florida, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Hamzavi Dermatology
Fort Gratiot, Michigan, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Start Date
December 1, 2009
Primary Completion Date
May 20, 2011
Completion Date
May 20, 2011
Last Updated
July 3, 2024
NCT06979453
NCT07116967
NCT07250802
NCT07449702
NCT07290569
NCT06888193
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions